Also, another factor that greatly complicates the impact of DSA in liver allograft dysfunction has been the variable induction therapies used between centers, which range from the use of a full course of anti-thymocyte immunoglobulin to steroid-only protocols [8,11,17]. You will find two classical HLA antigens, HLA class I and class II, that are the most recognized antigens to be involved in transplant. DSA were less strong (mean switch, 47%,p= 0.15). Importantly, non-DSA anti-HLA antibodies remained unchanged throughout the perioperative period, suggesting the mechanism(s) by which the liver lowers DSA levels are specific to the DSA. These data demonstrate the immunologic benefit of performing SLK is usually lasting and occurs very shortly after liver reperfusion. Keywords:Simultaneous liver-kidney transplant, Donor specific antibody, Sensitized == 1. Introduction == Kidney transplant recipients with pre-formed donor specific antibodies (DSA) have a higher incidences of acute and chronic antibody mediated rejection (AMR) [[1],[2],[3],[4]]. The presence of DSA can lead to worse renal allograft outcomes and, in the pretransplant setting, may be considered a contraindication to transplant [[1],[2],[3],[4]]. However, at least in the short-term, the liver appears to be immunologically privileged compared to the kidney, in that the liver appears to be refractory Citicoline to high levels of DSA. Furthermore, the liver may provide immunological cover in dual organ recipients with high levels of circulating anti-human leukocyte antigen (HLA) antibodies. The duration and exact mechanism(s) of this protection are largely unknown, but the immunologic protection from the liver can overcome some core immunologic tenets of transplantation, allowing for successful transplantation in the face of both a positive anti-human globulin complement-dependent cytotoxic (AHG-CDC) crossmatch and a high level of DSA without requiring prior desensitization [5,6]. Although AMR is Citicoline usually occasionally reported in liver recipients, it is widely accepted that high levels of DSA are not a contraindication to transplant [7]. However, the importance of humoral immune sensitization in liver transplants is still controversial. There is persuasive evidence that detection of circulating DSA in liver recipients serum is usually a contributing factor to short- and long-term graft dysfunction [[8],[9],[10],[11]]. Regrettably, there is very little or no routine immunological assessment performed for liver or simultaneous liver-kidney transplants (SLK) mainly due to the lack of hyperacute rejection and the well-known effect the liver has on lowering the humoral immune response risk [7,10,[12],[13],[14],[15],[16]]. Also, another factor that greatly complicates the impact of DSA in liver allograft dysfunction has been the variable induction therapies used between centers, which range from the use of a full course of anti-thymocyte immunoglobulin to steroid-only protocols [8,11,17]. You will find two classical HLA antigens, HLA class I and class II, that are the most recognized antigens to be involved in transplant. Importantly in terms of transplant, antibodies against these HLA antigens can be DSA or non-DSA. Interestingly, recent studies have described the liver as providing preferential protection against anti-HLA class I DSA, but prolonged anti-HLA class II DSA could be associated with rejection, suggesting that this liver may not be impervious to alloantibodies [18,19]. Although transplant centers have embraced the immune-privileged state of the liver, to our knowledge, there are very few studies assessing the impact of perioperative management and surgical techniques on pre-transplant DSA levels. Importantly, the optimal timing of the renal transplant during SLK has been debated from an immunologic standpoint with some programs delaying kidney transplant from 6 to 24 h, while other programs perform the transplant with no delay [6]. The decision to delay transplant may lead to increased chilly/ischemia time around the kidney, increased undue stress on the individual, and increased Citicoline inflammation, all leading to decreased allograft survival. In this study, in addition to demonstrating Citicoline the security of avoiding strong induction immunosuppression, we aim to show that delay is usually unnecessary Keratin 16 antibody when transplanting the kidney into a highly-sensitized recipient in a sequential liver-kidney transplant. In creating an evidence-based approach to the practice of delaying kidney transplant in highly sensitized patients, we focused on understanding the immediacy and extent of the protective effect of the liver during SLK in this pilot study. To this end, we recognized highly sensitized SLK candidates and monitored the level of anti-HLA antibodies peri- and intra-operatively to assess the kinetics of anti-HLA antibody levels during allograft reperfusion. == 2. Methods == == 2.1. Patient selection == Within the study period (September 2016 December 2018), subjects were included if they were actively a candidate for SLK and experienced documented DSA at the time of organ offer (n= 7). Inclusion criteria mandated that patients receive SLK.